Amgen AMGN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Aranesp | $1.36B-2.1% | $1.39B+1.8% | $1.36B+1.5% | $1.34B+0.8% | $1.33B-0.7% | |
| BLINCYTO | $1.6B+2.9% | $1.56B+2.1% | $1.53B+4.4% | $1.46B+8.9% | $1.34B+10.4% | |
| ENBREL | $2.04B-8.5% | $2.23B-17.8% | $2.71B-8.3% | $2.95B-9.4% | $3.26B-1.7% | |
| EVENITY | $2.22B+5.7% | $2.1B+8.7% | $1.93B+7.9% | $1.79B+7.6% | $1.66B+6.4% | |
| KRYSTEXXA | $1.36B+1.4% | $1.34B+7.1% | $1.25B+0.8% | $1.24B+4.6% | $1.19B+0.1% | |
| KYPROLIS | $1.42B+0.4% | $1.41B-1.5% | $1.43B-1.3% | $1.45B+0.1% | $1.45B-3.5% | |
| Nplate | $1.62B+6.5% | $1.52B+3.3% | $1.48B+0.1% | $1.48B+1.6% | $1.45B-0.3% | |
| Otezla | $2.26B-0.3% | $2.27B0.0% | $2.26B+0.9% | $2.24B+3.4% | $2.17B+2.0% | |
| Other products | $7.14B+0.7% | $7.09B+7.7% | $6.59B+8.0% | $6.1B+6.4% | $5.73B+1.8% | |
| Prolia | $4.04B-8.4% | $4.41B-2.5% | $4.53B+2.1% | $4.43B-1.0% | $4.47B+2.3% | |
| TEPEZZA | $2.01B+5.7% | $1.9B-0.2% | $1.91B+3.9% | $1.83B+1.4% | $1.81B-2.3% | |
| TEZSPIRE | $1.54B+3.9% | $1.48B+13.7% | $1.3B+9.1% | $1.19B+10.0% | $1.08B+11.5% | |
| Vectibix | $1.2B+1.7% | $1.18B+6.6% | $1.1B+0.2% | $1.1B+3.3% | $1.07B+1.9% | |
| XGEVA | $1.93B-7.4% | $2.08B-5.2% | $2.2B-0.1% | $2.2B-1.3% | $2.23B+0.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amgen break its business down?
- Amgen (AMGN) reports total revenues by product across 18 parts — Aranesp, BLINCYTO, ENBREL, EVENITY and IMDELLTRA/IMDYLLTRA. Each is extracted from the segment footnotes and tracked over time.
- Where does Amgen's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amgen's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
